Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 September 2020Big PharmaMuireann Bolger

Gilead signs deal to license new cancer treatment

Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.

More on this story

Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers